Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Evaluation of the HemoCue WBC DIFF in leukopenic patient samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Hereditary xerocytosis and familial haemolysis due to mutation in the PIEZO1 gene: a simple diagnostic approach

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. The molecular profile of mucosal melanoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The current epidemic of HPV-associated oropharyngeal cancer: An 18-year Danish population-based study with 2,169 patients

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. A distinctive epigenetic ageing profile in human granulosa cells

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Estimating narrow-sense heritability using family data from admixed populations

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

INTRODUCTION: Gene expression profiling (GEP) risk models in multiple myeloma are based on 3'-end microarrays. We hypothesized that GEP risk signatures could retain prognostic power despite being translated and applied to whole-transcript microarray data.

METHODS: We studied CD138-positive bone marrow plasma cells in a prospective cohort of 59 samples from newly diagnosed patients eligible for high-dose therapy (HDT) and 67 samples from previous HDT patients with progressive disease. We used Affymetrix Human Gene 1.1 ST microarrays for GEP. Nine GEP risk signatures were translated by probe set match and applied to our data in multivariate Cox regression analysis for progression-free survival and overall survival in combination with clinical, cytogenetic and biochemical risk markers, including the International Staging System (ISS).

RESULTS: Median follow-up was 66 months (range 42-87). Various translated GEP risk signatures or combinations hereof were significantly correlated with survival: among newly diagnosed patients mainly in combination with cytogenetic high-risk markers and among relapsed patients mainly in combination with ISS stage III.

CONCLUSION: Translated GEP risk signatures maintain significant prognostic power in HDT myeloma patients. We suggest probe set matching for GEP risk signature translation as part of the efforts towards a microarray-independent GEP risk standard. (ClicinalTrials.gov identifier: NCT00639054).

OriginalsprogEngelsk
TidsskriftInternational Journal of Laboratory Hematology (Print Edition)
Vol/bind38
Udgave nummer3
Sider (fra-til)298-307
Antal sider10
ISSN1751-5521
DOI
StatusUdgivet - jun. 2016

ID: 49300361